Defect driving resistance to CAR T therapy identified A CAR T cell interacting with a cancer cell. Defect driving resistance to CAR T therapy identified A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.
Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy An artist’s illustration of nanoparticles transporting mRNA into a T cell (blue), allowing the latter to express surface receptors that recognize cancer cells (red). (Image: Ryan Allen, Second Bay Studios) Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.
Deciphering a cancer treatment’s dark side Penn In the News Science Deciphering a cancer treatment’s dark side Saar Gill of the Perelman School of Medicine said it would be easier to treat cancer using CAR-T cell therapy without the looming possibility of triggering cytokine release syndrome. Lab-grown brain organoids, rapidly deployed, can fight glioblastomas Lab-grown brain organoids, rapidly deployed, can fight glioblastomas Glioblastoma organoids grown from patients’ own glioblastoma tissue can be used to investigate personalized treatment approaches in time-sensitive cases. An entire course of radiation treatment in under one second An entire course of radiation treatment in under one second Findings related to FLASH radiotherapy—using protons rather than electrons—prove feasible in the future for cancer therapy. Proton therapy lowers risk of side effects in cancer patients Proton therapy lowers risk of side effects in cancer patients Proton therapy leads to a significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation. Cure rates between the two groups are almost identical. Using radiomics to predict breast cancer Using radiomics to predict breast cancer Penn researchers can predict 10-year breast cancer recurrence with MRI scans that characterize the genetic makeup of tumors, allowing for individualized, non-invasive treatment. Promising findings for multiple myeloma immunotherapy Promising findings for multiple myeloma immunotherapy Adam Cohen of the Perelman School of Medicine headed a clinical trial that found an experimental therapy can make a difference for patients who have exhausted other options. Engineering the immune system to tackle glioblastoma Engineering the immune system to tackle glioblastoma Immunotherapy is a “game changer” for improving outcomes in treating Glioblastoma Multiforme, the most common, and most lethal, malignant brain tumor in adults. A new role for a triple-negative breast cancer target A new role for a triple-negative breast cancer target A team led by Rumela Chakrabarti of the School of Veterinary Medicine has made new discoveries into how a key protein involved in triple-negative breast cancer functions in puberty.
Lab-grown brain organoids, rapidly deployed, can fight glioblastomas Lab-grown brain organoids, rapidly deployed, can fight glioblastomas Glioblastoma organoids grown from patients’ own glioblastoma tissue can be used to investigate personalized treatment approaches in time-sensitive cases.
An entire course of radiation treatment in under one second An entire course of radiation treatment in under one second Findings related to FLASH radiotherapy—using protons rather than electrons—prove feasible in the future for cancer therapy.
Proton therapy lowers risk of side effects in cancer patients Proton therapy lowers risk of side effects in cancer patients Proton therapy leads to a significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation. Cure rates between the two groups are almost identical.
Using radiomics to predict breast cancer Using radiomics to predict breast cancer Penn researchers can predict 10-year breast cancer recurrence with MRI scans that characterize the genetic makeup of tumors, allowing for individualized, non-invasive treatment.
Promising findings for multiple myeloma immunotherapy Promising findings for multiple myeloma immunotherapy Adam Cohen of the Perelman School of Medicine headed a clinical trial that found an experimental therapy can make a difference for patients who have exhausted other options.
Engineering the immune system to tackle glioblastoma Engineering the immune system to tackle glioblastoma Immunotherapy is a “game changer” for improving outcomes in treating Glioblastoma Multiforme, the most common, and most lethal, malignant brain tumor in adults.
A new role for a triple-negative breast cancer target A new role for a triple-negative breast cancer target A team led by Rumela Chakrabarti of the School of Veterinary Medicine has made new discoveries into how a key protein involved in triple-negative breast cancer functions in puberty.